
State Street Consumer Discretionary Select Sector SPDR ETF (XLY)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn more- Previous Close
116.84 - Open
118.50 - Bid 117.85 x 130000
- Ask 118.18 x 20000
- Day's Range
116.43 - 118.67 - 52 Week Range
98.34 - 125.01 - Volume
9,519,831 - Avg. Volume
10,839,479 - Net Assets 21.45B
- NAV 118.33
- PE Ratio (TTM) 31.92
- Yield 0.82%
- YTD Daily Total Return -0.69%
- Beta (5Y Monthly) 1.25
- Expense Ratio (net) 0.08%
Performance Overview: XLY
View MoreTrailing returns as of 4/30/2026. Category is Consumer Cyclical.
People Also Watch
Holdings: XLY
View MoreTop 10 Holdings (70.24% of Total Assets)
Sector Weightings
Recent News: XLY
View MoreResearch Reports: XLY
View More-
Biogen Earnings: Strong First Quarter, Eventful Year Ahead
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
RatingPrice Target -
Biogen Earnings: Eventful Year Ahead Despite Expected Decline in Revenue
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
RatingPrice Target -
AI driving growth, raising target price to $450
Taiwan Semiconductor Manufacturing Company Ltd., headquartered in Hsinchu, Taiwan, was founded in 1987 and pioneered the pure-play foundry or 'merchant fab' model. The company serves both integrated semiconductor producers who outsource a portion of their production as well as 'fabless' semiconductor producers who outsource all manufacturing. Taiwan Semi serves over 500 semiconductor customers, producing more than 11,500 distinct products while providing a broad range of advanced, specialty, and advanced packaging technologies.
RatingPrice Target -
ASML Earnings: Outlook Is Magnificent, but Valuation Overshoots Our Fair Value Estimate
ASML is the leader in lithography systems for manufacturing semiconductors with 90% market share. Lithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. Lithography allows chipmakers to increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML’s largest clients are TSMC, Samsung, Intel, SK Hynix, and Micron.
RatingPrice Target




